Compare KRRO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | TTRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.1M | 116.0M |
| IPO Year | N/A | N/A |
| Metric | KRRO | TTRX |
|---|---|---|
| Price | $11.63 | $3.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $54.60 | $8.00 |
| AVG Volume (30 Days) | ★ 294.9K | 31.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.20 | $2.57 |
| 52 Week High | $55.89 | $26.50 |
| Indicator | KRRO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 31.93 |
| Support Level | $10.81 | $3.55 |
| Resistance Level | $12.46 | $3.80 |
| Average True Range (ATR) | 1.11 | 0.27 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 16.69 | 2.35 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.